Genable Technologies, based in Trinity College, has secured €5m in financing.  This fund will help progress its gene therapy technology to develop new cures for retinitis pigmentosa, a disease that can lead to blindness, specifically to progress the development of its lead test product GT038 retinitis pigmentosa forward into clinical evaluation test trials on humans.

The biopharmaceutical firm is developing new gene medicines to treat 'dominant' genetic diseases based on the work of Prof. Jane Farrar, Dr Paul Kenna and Prof. Peter Humphries at Trinity College Dublin (TCD).


Newsletters Newsroom Suppliers and Services Directory